)
NEWS
Media Contacts:
Seqirus news releases
Seqirus news releases
New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.
Seqirus opens new Centre of Excellence in Amsterdam
New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit.
Seqirus and Laboratoire Arrow sign Distribution Agreement in France
This news release is intended for Health Professional media only.
Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
This news release is intended for Health Professional media only.